期刊
DIABETES THERAPY
卷 5, 期 2, 页码 355-366出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s13300-014-0089-4
关键词
Anti-diabetic drugs; Cardiovascular safety; Canagliflozin; Dapagliflozin; Empagliflozin; Perineal hygiene; Sodium-glucose co-transporter-2 inhibitors
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据